CEL-SCI Corporation (CVM)
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
$67.64M
Mr. Geert R. Kersten Esq.
43.00
Vienna, VA
Dec 08, 1983
-1.90
$-0.58
0.07
0.64
0.00%
-2.30
-0.05
7.71
0.00
0.18
-118.17%
-233.88%
Similar stocks (4)
BioCryst Pharmaceuticals, Inc.
BCRX
Agenus Inc.
AGEN
Aeterna Zentaris Inc.
AEZS
Cyclacel Pharmaceuticals, Inc.
CYCC
ETF Exposure (12)
ETFMG Treatments, Testing and Advancements ETF
GERM
0.16%
iShares Micro-Cap ETF
IWC
0.01321%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (4)
BioCryst Pharmaceuticals, Inc.
BCRX
Agenus Inc.
AGEN
Aeterna Zentaris Inc.
AEZS
Cyclacel Pharmaceuticals, Inc.
CYCC
ETF Exposure (12)
ETFMG Treatments, Testing and Advancements ETF
GERM
0.16%
iShares Micro-Cap ETF
IWC
0.01321%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%